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 Acute Myeloid Leukemia (AML) is a disease of dismal prognosis, with a 5-year 
survival of under 40% that has remained unmodified for the last 3 decades. Sequencing 
analyses of patient samples have identified recurrent mutations and highlighted 
associated common disease mechanisms, which have putative therapeutic value. 
Additionally, loss-of-function genetic or expression knockdown screens can be used to 
identify individual factors required for disease maintenance that may not be targeted by 
mutation. A recent drop-out screen based on Clustered Regularly Interspaced Short 
Palindromic Repeats with the Cas9 endonuclease technology (CRISPR/Cas9) identified 
MAT2A (methionine adenosyltransferase2A) as a susceptibility gene in at least some 
forms of AML.  
In the work reported in this thesis, I aimed to validate the results of the screen by 
confirming dependency of cultured AML cells on MAT2A expression. I selected AML 
cell lines representing distinct common subtypes of human leukaemia, and evaluated the 
effects of knocking-out MAT2A through CRISPR/Cas9 gene editing technology. As a 
complementary strategy, I developed and validated RNA interference (RNAi) tools for 
MAT2A expression knockdown, which are also amenable for testing in AML patient 
samples. I observed that MAT2A loss resulted in reduced proliferation and survival of 
cultured AML cells. These results are currently being pursued mechanistically with a 






A Leucemia mieloide aguda (LMA) é uma doença com um prognóstico bastante 
reservado, na qual menos de 40% dos doentes sobrevivem até 5 anos após diagnóstico 
da doença, sendo que esta percentagem permaneceu inalterada desde as últimas 3 
décadas. As análises de sequenciação de amostras de pacientes identificaram mutações 
recorrentes e destacaram mecanismos associados, que têm valor terapêutico putativo. 
Além disso, fazer um screen para avaliar perdas de função genética ou mesmo 
knockdown de expressão de genes, pode ser útil na medida em que certos fatores 
individuais podem ser necessários para a manutenção da doença sem que estes sejam 
alvo de mutação. Um recente drop-out screen, que tem como base ir avaliando as 
consequências da perda individual de todos os fatores, baseada na tecnologia CRISPR, 
que consiste em pequenas porções do DNA bacteriano compostas por repetições de 
nucleotídeos, associada à endonuclease Cas9 (CRISPR/Cas9) identificaram o gene 
MAT2A (metionina adenosiltransferase2A) como um gene susceptível em pelo menos 
algumas formas de LMA. 
No trabalho exposto nesta tese, pretendi validar os resultados desse screen, 
confirmando a dependência das células com LMA cultivadas sobre a expressão de 
MAT2A. Selecionei linhas celulares com LMA que representavam subtipos comuns 
distintos de leucemia humana e avaliei os efeitos do knockout de MAT2A através da 
tecnologia de edição de genes CRISPR / Cas9. Como uma estratégia complementar, 
desenvolvi e legitimei ferramentas de RNA interferência (RNAi) para o knockdown de 
expressão de MAT2A, que também pode ser testado em amostras de pacientes com 
LMA. Observei que a perda de MAT2A resultou numa diminuição da proliferação e da 
sobrevivência nas células cultivadas com LMA. Estes resultados estão atualmente a ser 








1.1. Acute myeloid leukemia 
Acute Myeloid Leukemia (AML) is a clonal hematopoietic disorder of 
undifferentiated myeloid precursors (blasts), characterized by abnormal expansion of 
immature white blood cells in the bone marrow, with accompanying impairment of 
normal hematopoiesis (1). Prognosis is dependent upon several factors, including 
subtype of AML, age and other chronic medical conditions. It is estimated to comprise 
around 34% of all cases of leukaemia in 2017 (2).  
Leukemia is the name given to the white blood cells cancer and it is divided into 
4 specific types, particularly with a myeloid or lymphocytic origin and an acute or 
chronic development. “Acute” implies fast disease progression if not treated and 
“Myeloid” refers to the type of cell this leukemia starts from. Conventional treatments 
of chemotherapy or even hematopoietic stem cell transplant have not changed for 
decades, so that it is urgent to find alternative ways to overcome the disease. 
AML is clinically and molecularly heterogeneous (3). One system commonly 
used for AML classification is the French-American-British (FAB) classification. It 
divides the disease into subtypes, M0 through M7, based on the type of cell from which 
the leukemia develops and how mature the cells are (Table 1). 
 
 
Table 1 - FAB classification of Acute Myeloid Leukemia, highlighting some morphological 
characteristics as well as the prevalence of each type in adult patients with AML. *Prevalence in adult 
AML patients. Ref: Hoffman, 2010 (4); Acute Myeloid Leukemia Staging, Internet, accessed 12-10-2017 
(5). 
 
FAB classification Characteristics Prevalence*  
M0 
Undefined acute 
myeloblastic leukemia.  





Blast cells, agranular and 





leukemia with minimal 
maturation 





Abnormal promyelocytes with 




Sum of myeloblasts, 
promyelocytes, myelocytes and 













Acute erythroid leukemia Erythroid components exceed 




More than 30% of nucleated 
cells are blasts 5% 
 
Each particular type of AML, according to FAB  classification, is characterized 
by a high degree of heterogeneity in what concerns chromosomal abnormalities and 
gene mutations, which may coexist together in leukemic cells (6).  
Non-random chromosomal abnormalities, such as translocations, that result in 
functional gene arrangements, and production of oncogenic fusion proteins, have been 
found in more than 60% of patients with AML. Amongst these, I highlight the 
translocations between chromosomes 8 and 21 (t(8;21)), resulting in the RUNX1-
RUNX1T1 fusion protein; between chromosomes 15 and 17 (t(15;17)), with synthesis 
of PML-RARα; and multiple rearrangements of chromosome 11q23 resulting in fusion 
proteins involving Mixed Lineage Leukemia (MLL) gene. 
Table 2 shows the most frequent translocations with the respective chromosomal 
location, resulting onco-fusion proteins, and their effect on AML cells. In general, 
translocations are associated with transcriptional re-programming (7). For example, 
RUNX1– RUNX1T1 down-regulates expression or activity of PU.1, C/EBPα and 
RUNX1. These are important to guide the most primitive lineages into committed and 
differentiated cells regarding myeloid path during hematopoiesis and a loss of function 





Table 2 - Examples of transcription factor mutations in patients with AML, regarding the chromosomal 
location, the frequency that occur in AML patients and the most common FAB subtype associated. AML, 
acute myeloid leukaemia; CBFβ, core-binding factor-β; C/EBPα, CCAAT/enhancer binding protein-α; 
FAB, French–American–British; MLL, mixed lineage leukaemia; H3K4, lysine 4 in histone H3; MYH11, 
myosin heavy chain 11; PML, promyelocytic leukaemia; PU.1, transcription factor encoded by SPI1; 














Acts as a transcriptional repressor that 
interferes with gene expression programs 
involved in differentiation, apoptosis and 
self-renewal. It can suppress PU.1 







Dominant negative regulator of wild-type 
RUNX1, PU.1 and suppress C/EBPα 








Inv(16) disrupts the gene encoding the 
RUNX1 co-factor, core binding factor β 
(CBFβ). CBFβ is a small protein that 
allosterically regulates the ability of 
RUNX1 to bind to DNA and that blocks 
the ubiquitin-mediated degradation of 
RUNX1. 
8% M4 (13) 
MLL-fusions t11q23 
Leukaemogenic MLL translocations 
encode MLL fusion proteins that have lost 
H3K4 methyltransferase activity. A key 
feature of MLL fusion proteins is their 
ability to efficiently transform 
haematopoietic cells into leukaemia stem 
cells. 
10% M4/M5 (14) 
 
 Kasumi1, one of the cell lines used to perform experiments, was the chosen one 
to represent the particular type of RUNX1-RUNX1T1 oncofusion protein. As described, 
Kasumi1 has a translocation that gives rise to RUNX1- RUNX1T1 protein, down-
regulating C/EBPα mRNA, protein and DNA binding activity, which is crucial for the 
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differentiation of granulocytes. Also, two MLL-fusions of mouse models were used, 
MLL/AF4 and MLL/AF9 and one human MLL-fusion, MOLM-13, as well. Both 
Kasumi1, MOLM-13 and MLL/AF4 and MLL/AF9 are described later in Materials and 
Methods. 
On the other hand, leukemias with a normal karyotype, carry mutations in genes 
such as FLT3, nucleophosmin NPM1 and DNMT3A (15). That can cause a loss of 
coordination between proliferation and differentiation in the hematopoietic progenitor 
cell pool. 
Table 3 shows the most relevant gene mutations for this thesis with the 
respective chromosomal location, and their effect on AML cells. 
 
Table 3 - Examples of gene mutations in patients with AML, regarding the chromosomal location, the 
frequency that occur in AML patients. AML, acute myeloid leukaemia; C/EBPα, CCAAT/enhancer 
binding protein-α; MLL, mixed lineage leukaemia; NPM1, Nucleo-phosmin 1; FLT3, fms like tyrosine 
















Some functions of NPM1 protein in-
clude binding of p53, initiate centrosome 
duplication and ribosomal protein as-
sembly and transport. This mutation has 












FLT3 gene encodes a class III receptor 
tyrosine kinase (RTK). This receptor 
synergizes with growth factors to stimu-
late proliferation of stem cells, progeni-
tor cells, dendritic cells, and natural 
killer cells. ITD consists in a duplication 
in amino acids in the juxtamembrane 
(JM) domain. These repeat sequences 













domain resulting in constitutive tyrosine 
kinase (TK) activation, leading to leu-
kemogenesis once TKs can no longer 
control cellular events like proliferation, 




This gene encodes a member of BCL2 
protein family. The protein is responsi-
ble for activating apoptosis by aiding in 
the opening of the mitochondrial volt-
age-dependent anion channel to release 
cytochrome c. The expression of this 
gene is regulated by the tumor suppres-
sor P53 and has been shown to be in-














Ras proteins belong to the super family 
of small GTPases and it is comprised of 
three homologues, HRAS (11p15.5), 
KRAS (12p12.1), and NRAS (1p13.2).  
They cycle between the active GTP-
bound form and the inactive GDP-bound 
form. Mutations within the RAS gene 
result in constitutive activation of the 
RAS GTPase. The result is a sustained 
proliferation signal within the cell, even 


















The DNMT3A gene encodes the DNA 
methyltransferase 3A, an enzyme that 
catalysis the process of de novo DNA 
methylation, and as such, plays a role in 
cancer development through deregula-
tion of gene expression. DNMT3A mu-
tations most often occur at the R882 
residue of the protein, and they are be-
lieved to cause loss of function or may 
induce epigenetic changes by affecting 
the DNA methyl-transferase activity, 








As previously said, mouse models MLL/AF4 and MLL/AF9 which have 
FLT3ITD/+ mutation as well were used to perform experiments. FLT3ITD/+ MLL/AF4 and 
MLL/AF9 are described later in Materials and Methods.  
Moreover, human AML cell line, MOLM-13, carries a CBL-ΔExon8 mutation 
(28) which can lead to dysregulation of receptor tyrosine kinases and have the potential 
to transform hematopoietic cells by constitutively activating the FLT3 pathway (29). 
This means that MOLM-13 cell line carries an ITD mutation of FLT3 kinase as well.  
Apart from those, Oci-AML3s carry also mutations in BAX and Ras proteins 
(see table 3). 
  
1.2. Gene Editing 
As previously stated, gene editing was utilized through CRISPR Cas9 technolo-
gy in a drop-out screen for genetic vulnerabilities in AML cell lines. This work presents 
the same approach of CRISPR/Cas9 system genetic engineering, which offers the abil-
ity to target and study precise DNA sequences in the vast expanse of a genome. 
CRISPR functions as an adaptive immune system in bacteria (30), which can target spe-
cific sequences of foreign nucleic acids. It relies on Cas9 endonuclease, which cause 
double-stranded cleavage to any target location in DNA sequence, determined by a sin-
gle guide RNA (sgRNA) and can lead to a specific gene knockout (KO), by stopping 
the transcription of the target gene (31). Figure 1 schematizes the CRISPR/Cas9 system 

















Figure 1 - CRISPR-Cas9 target recognition. The sgRNA (in green) hybridizes with the strand opposite 
the PAM site (in red), where the transcript RNA (in yellow) is important to binding the Cas9 protein. 
After, the Cas9 nuclease cuts the DNA, giving rise to a site-specific double strand DNA (dsDNA) break. 
Ref: Moore, C.B. et al., 2010 (32). 
 
 
Moreover, we took advantage of another system, in order to achieve a target 
gene knockdown instead of a knockout, and it was possible through the technology 
of short hairpin RNAs (shRNA). shRNAs are sequences of RNA that include a region 
of internal hybridization that creates a tight hairpin structure which can be used to si-
lence target gene expression via RNA interference (RNAi). Expression of shRNA in 
cells can be achieved by plasmids delivery or through infection of the cell with virally 
produced vectors (33). Lentiviral delivery of the shRNA enables stable expression and 
permanent knockdown of the target gene. After the vector integrates the host genome, 
shRNA is formerly transcribed in the nucleus by polymerase III from U6 promoter in 
the nucleus. The product, pri-miRNA, is processed by Drosha (class II ribonuclease 
enzyme) into a hairpin shaped precursor miRNAs (pre-miRNA). The resulting pre-
miRNA is exported to the cytosol by nuclear export receptor Exportin 5. This product is 
then processed by the endoribonuclease enzyme Dicer, which converts the shRNA into 
the siRNA duplexes (34), and loaded into the RNA-induced silencing complex (RISC). 
The sense strand is rapidly destroyed and the antisense, which is the guide strand, di-
rects RISC to mRNA that has a complementary sequence. In the case of perfect com-
plementarity, RISC cleaves the mRNA. In the case of impaired complementarity, RISC 





























Figure 2 – shRNAs mechanism. Lentiviral delivery and machinery of RNA interference (iRNA) in 
mammalian cells until the last step of translational suppression or mRNA cleavage. GAG indicates 
glycosaminoglycans; VSVg, component of vector envelope. Ref: Cojocari, D., 2010 (37). 
 
 
1.3. Acute Myeloid Leukemia and MAT2A 
 
Methionine adenosyltransferase 2A, known as MAT2A, a subunit of MAT2 en-
zyme, utilizes L-methionine (Met) and adenosine 5′-triphosphate (ATP) to form SAM 
(S-adenosyl-L-methionine), the universal methyl donor for methylation reactions, like 
histone and DNA methylation, for instance. This event befalls in a three-part cycle rep-
resented in Figure 3, where the folate and the methionine cycles are presented, together 
with histone methylation. In this last one, histone methyltransferases (HMT) donate the 
SAM methyl group to their histone substrates, producing S-adenosylhomocysteine 
(SAH). In turn, SAH is hydrolysed to homocysteine (hCys) and to complete the cycle, 
hCys is then metabolized through two major pathways: methylation and trans-
sulfuration (38). Under normal conditions, approximately 50% of hCys is re-methylated 
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to form methionine which, in most tissues, occurs via methionine synthase (MS) by 
donation of a methyl group from 5-methyltetrahydrafolate (5-mTHF)(39) or hCys may 
also be converted to methionine via betaine–homocysteine S-methyltransferase 




Figure 3 - One-carbon metabolism and histone methylation. Methionine adenosyltransferase (MAT) uses 
methionine (MET) to form S-Adenosylmethionine (SAM) and histone methyltransferases (HMTs) utilize 
SAM to donate a methyl group to their histone substrates. While histone demethylases (HDMs) remove 
the methyl group from histones now methylated, the resulted S-adenosylhomocysteine (SAH) is converted 
to homocysteine (hCys) via S-adenosylhomocysteine hydrolase (SAHH). In turn, hCys can be 
remethylated to regenerate MET by donation of a methyl group from 5-methyltetrahydrafolate (5-mTHF) 
via methionine synthase (MS) or from betaine via betaine–homocysteine S-methyltransferase (BHMT). 
Ref: Mentch, S.J., Locasale, J.W., 2015 (39) 
 
The trans-sulfuration pathway, Figure 4, involves the interconversion of hCys, 
through the intermediate cystathionine, by CBS (cystathionine β-synthase), which is the 
immediate precursor to cysteine. Cysteine is utilized in the synthesis of glutathione, a 
tripeptide that reduces reactive oxygen species (ROS), thereby protecting cells from 
oxidative stress (41). This is important as, depending on demand, metabolism of homo-
cysteine can be redirected to increase methylation potential, by producing methionine, 




Figure 4 - Methionine cycle and trans-sulfuration pathway. Glutathione synthesis starts with the conver-
sion of homocysteine into cystathionine, which is dependent on the presence of both serine and cystathi-
onine β-synthase. Cystathionine origins cysteine by cystathionase and with a loss of a- ketobutyrate. In 
turn, cysteine origins γ-glutamylcysteine with the use of glutamine and γ-glutamylcysteine ligase, and 
finally, depending on glycine and glutathione synthetase, glutathione is formed. 
Ref: Adapted from: Hitchler, M.J., Domann, F.E., 2007  (42). 
 
Focusing on the methionine downstream product, S-Adenosylmethionine 
(SAM), it is the principal methyl donor in the cell. Epigenetic modifications, such as 
histone modifications, are important in the establishment of chromatin states that con-
trol gene expression and DNA accessibility. Those are crucial to normal development 
and differentiation of distinct cell lineages in the adult organism. SAM donates methyl 
residues for methylation of DNA, RNA, proteins and lipids by a variety of methyltrans-
ferases. MAT is thus a critical cellular enzyme that catalyses SAM production from 
methionine and participates in key metabolic pathways. 
Almost 60 years ago, Sugimura et al. (43) indicated that methionine metabolism 
is fundamental for cancer cell proliferation. There is direct evidence that noncancerous 
cells can thrive without methionine, while in various cancers, cells cannot, even when 
hCys is present (44,45). The higher the metastatic potential of the cell line, the higher 
the concentration of methionine required to maintain its proliferation (46). The mecha-
nisms responsible for methionine dependence in malignant cell lines are not fully un-
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derstood but it is known that methionine-dependent cells endogenously synthesize me-
thionine at normal levels in homocysteine media but show reduced SAM synthesis (4). 
Also, when SAM is added to hCys medium, methionine-dependent breast cancer cells 
could proliferate, implying that some cancer cells are especially sensitive to SAM limi-
tation (47). 
There are two forms of MAT (see Figure 5): MAT I/III that is encoded by the 
MAT1A gene and is expressed in the liver; and MATII, encoded by MAT2A, which is 
widely distributed in non-hepatic tissues and which enzymatic activity is regulated by 
an associated subunit, MAT2B (48,49). MAT2A is thus the primary enzyme catalysing 
SAM production in most cell types, including cancer cells, and also during develop-
ment, including in the developing fetal liver, where MAT2 predominates. Progressively, 
fetal liver MAT2 is replaced by the liver-specific isoforms during development (50). 
 
Figure 5 – Dimeric composition of MAT enzyme. MAT1A and MAT2A encode two MAT catalytic subu-
nits, α1 and α2, correspondingly. The α1 subunit organizes into dimers (MATIII) or tetramers (MATI). 
The α2 subunit is found in the MATII isoform. A third gene MAT2B, encodes a regulatory subunit β, that 
regulates the activity of MATII. Adapted from: Cai, J., et al., 1998 (51) 
 
MAT2A plays an important role in solid cancers. It was shown that a switch in 
MAT expression in liver, from MAT1A to MAT2A, played an important pathogenic role 
in promoting liver cancer growth (52) and that silencing of MAT2A expression resulted 
in inhibition of cell growth and induction of apoptotic cell death in human hepatoma 
cells (53). Similar to the liver, overexpression of MAT2A has been found in other human 
solid tumors, including colon cancer (54) and breast cancer (55).  
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A CRISPR Drop-out Screen of genetic vulnerabilities in human AML cell lines 
published collaboratively by the Pina lab (22) identified MAT2A as being required for 
AML maintenance in 4 out of 5 cell lines (figure 6). 
 
 MOLM13 MV4-11 HL-60 OCI-AML2 OCI-AML3 
MAT2A      
Figure 6 - Schematic representation of results of the Tzelepis et al CRISPR/Cas9 drop-out screen for 
MAT2A, evidencing the need of MAT2A for maintenance of AML cell lines. Significant p-values for gene 
drop-out represented in colour at different levels of FDR (yellow<20%; gold<10%; orange<5%; 
brown<1%); grey, not significant. Adapted by Pina lab from Tzelepis K., et al., 2016 (22). 
 
MAT2A role in leukemia, particularly AML, has not been explored to date. Giv-
en the importance of MAT2A for solid cancer development, I undertook validation of 
the screen results in AML cell lines representative of common forms of human disease. 
 
 Objectives  
 
The overarching goal of the research presented in this thesis is to extend the 
knowledge on the role of the MAT2A gene in Acute Myeloid Leukemia. To achieve 
this goal, I ablated expression of MAT2A in three human AML cell lines (Kasumi1, 
MOLM13 and Oci-AML3) and two transformed MLL-AF4 FLT3ITD and MLL-AF9 
FLT3ITD primary mouse bone marrow (BM) and evaluated consequences in terms of 





 Materials and methods 
3.1. Cell lines 
3.1.1. Mouse Cell Lines 
Mouse cell lines were obtained from FLT3ITD/+ mice background (20). These 
bone marrow cells were further engineered to express Cas9, by inserting the human 
EF1α promoter-driven Cas9 expression cassette, using a ubiquitous promoter, Rosa26 
promoter (22). 
The Cas9 FLT3 ITD/+ cells were then transformed by introducing a retrovirus con-
struct expressing either MLL/AF9, pMSCV-MLL-AF9-IRES-YFP (56) or MLL/Af4, 
pMSCV-MLL-AF4-PGK-puro (57). Afterwards, the cells were transplanted into 
recipients that were allowed enough time to develop leukemia (22). Leukemic cells 
from these mice were isolated, kept in culture, and consequently frozen. Cells were 
thawed and placed in culture accordingly with experimental needs, as described below.   
 
3.1.2. Human Cell Lines 
MOLM-13 cell line was established from the peripheral blood of a 20-year-old 
man with acute myeloid leukemia AML classified as a M5, accordingly to French–
American–British classification (FAB) (58).  
Oci-AML3 cell line was established from the peripheral blood of a 57-year-old 
man with acute myeloid leukemia classified as a FAB M4, accordingly to French–
American–British classification, at diagnosis in 1987 (58).  
Kasumi1 cell line was established from the peripheral blood of a 7-year-old Jap-
anese boy suffering from acute myeloid leukemia (AML). This is a leukemic cell line 
with an 8;21 chromosome translocation, that has characteristics of myeloid and macro-
phage lineages and it is classified as a FAB M2, accordingly with FAB classification 
(59). This translocation juxtaposes the RUNX1 with RUNX1T1 gene, which leads to 
chimeric RUNX1 – RUNX1T1 protein production. This protein down-regulates 
C/EBPα mRNA, protein and DNA binding activity, which is crucial for the differentia-
tion of granulocytes (60).  
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Last of all, epithelial 293T cell line is a highly transfectable derivative of human 
embryonic kidney 293 cells and contains the SV40 T-antigen, which means it is compe-
tent to replicate vectors carrying the SV40 region of replication. This embryonic kidney 
cell line, also called HEK293, is an adherent cell line, allowing the viral particles to be 
collected from the culture medium.  It has been widely used for high-titer retroviral pro-
duction, gene expression and protein production. To run the experiments, constructs that 
expressed retroviral packaging functions were stably introduced into 293T cells (61). 
 
3.2. Cell Culture 
FLT3 MLL/AF4-Cas9 and FLT3 MLL/AF9-Cas9 cell lines were cultured in 
RPIM 1640 (Roswell Park Memorial Institute 1640 Medium, Sigma-Aldrich) supple-
mented with 20% FBS (Fetal Bovine Serum, Sigma-Aldrich), 1% penicil-
lin/streptomycin ([peniciline]=100 units/mL and [streptomycin]=100µ/mL from Sigma-
Aldrich) and 1% L-glutamine (in a final concentration of 2 mM, from Sigma-Aldrich), 
in the presence of 10 ng ml-1 mIL-3 (Peprotech), added every other day to the culture. 
This cytokine would stimulate the cells to grow. These cell lines were cultured and di-
vided into the final concentration of 3 x 105 cell mL-1 and were incubated at 37 ºC and 
5% CO2.  
MOLM13, Oci-AML3 and Kasumi1 AML human cell lines were cultured in 
RPIM 1640 (Sigma-Aldrich) supplemented with 20% FBS (Sigma-Aldrich), 1% peni-
cillin/streptomycin ([peniciline]=100 units/mL and [streptomycin]=100µ/mL from Sig-
ma-Aldrich) and 1% L-glutamine (in a final concentration of 2 mM, from Sigma-
Aldrich). MOLM13 and Oci-AML3 cell lines were cultured and divided into the final 
concentration of 5 x 105 cell mL-1 and were incubated at 37 ºC and 5% CO2. Kasumi1 
line was cultured and divided into the final concentration of 0.7 x 106 cell mL-1 and was 
incubated at 37 ºC and 5% CO2. Lastly, K652 cell line was cultured and divided into the 
final concentration of 0.7 x 105 cell mL-1 and was incubated at 37 ºC and 5% CO2. All 
cancer cell lines were obtained from the Sanger Institute Cancer Cell Collection and 
negative for mycoplasma contamination (22). 
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293T/human embryonic kidney (HEK) cells, used to produce lentiviral con-
structs, were maintained in DMEM (Dulbecco’s Modified Eagle’s Medium, Invitrogen) 
supplemented with 10% FBS (Invitrogen), 1% Penicillin/Streptomycin ([peni-
ciline]=100 units/mL and [streptomycin]=100µ/mL from Sigma-Aldrich) and 1% L-
glutamine (in a final concentration of 2 mM, from Sigma-Aldrich). 
 
3.3. Plasmid construction  
3.3.1. pKLV2 vector for guideRNA.  
A lentiviral backbone vector, pKLV2, was previously generated in the study of 
“A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets 
in Acute Myeloid Leukemia” by Konstantinos Tzelepis and a partnership of Pina’s lab 
group (22). The plasmid pKLV-U6gRNA(BbsI)-PGKpuro2ABFP has been deposited 
with Addgene (ref: 50946).  
Guide RNAs are expressed through a RNA polymerase III U6 promoter. Inte-
gration of the gRNA is reported from the PGK (phosphoglycerate kinase) promoter, 
which is correlated with BFP (Blue Fluorescent Protein) expression cassette. Ampicillin 
resistance cassette is also present, which makes sure these plasmids can grow in an en-
vironment containing ampicillin, needed when cloning gRNAs (see Figure 7A). In order 
to insert guides for mouse Mat2a gene or human MAT2A gene, pKLV2 plasmid was 
previously digested (by Pina’s lab group) with BbsI in two sites giving rise to two sticky 




Figure 7 - A) Design of pKLV2 vector. Expresses gRNA under the pol III U6 promoter. The plasmid con-
tains a PGK promoter cassette to monitor expression of gRNAs. The bacterial plasmid is resistant to 
ampicillin, since the AmpR cassette is present. Restriction enzymes BbsI cut two sticky ends, which are 
responsible to attach the designed gRNAs, complementary to the restriction ends. B) Excerpt of pKLV2 
plasmid sequence where we can see the sequencing cut recognized by BbsI restricted enzymes, creating 
two sticky ends that bind guideRNAs for Mat2a and MAT2A genes. Figures created with SnapGene ® 
Viewer 3.3.3 program. 
 
3.3.2. LentiLox 3.7 vector for short hairpin RNA (shRNA). 
pLL3.7 (LentiLox 3.7) lentiviral vector, obtained beforehand, expresses shRNAs 
from a Polymerase III U6 promoter. Incorporation of the shRNA is reported from the 
CMV (cytomegalovirus) promoter, which is observed by GFP (Green Fluorescent Pro-
tein) expression cassette, that is correlated with shRNA expression. Ampicillin re-
sistance cassette is also present, which makes sure these plasmids can grow in an envi-
ronment containing ampicillin, needed when cloning gRNAs (see Figure 8A). The 
plasmid was digested with XhoI and HpaI restrict enzymes, using 1X CutSmart® Buffer 
(New England Biolabs, NEB). Restriction enzyme HpaI cuts the 3’ cloning site bluntly, 
where XhoI leaves a sticky end when cutting the 5’ cloning site, open for binding of the 
designed oligos to complement the restriction ends (see Figure 8B).  
After an incubation of 3h at 37°C, a 0.8% agarose gel was run for purification in 
1x TAE (Tris-acetate-EDTA, CIMR). SYBR Safe Gel Stain (Invitrogen) was added to 
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enable DNA visualization. A mix of 50 μL of the digested vector DNA with 10 µL 
loading dye (5x, QIAGEN) were loaded into the agarose gel divided between two wells. 
The gel was run for 2h and thereafter, linearized DNA was cut out from the gel and fur-
ther purified using QIAquick Gel Extraction Kit (QUIAGEN) (see Annexes, 7.2.). A 




Figure 8 - A) Design of pLL3.7 vector. Expresses shRNA under the pol III U6 promoter. The plasmid 
contains a CMV promoter cassette to monitor expression of shRNA. The bacterial plasmid is resistant to 
ampicillin, since the AmpR cassette is present. Restriction enzymes HpaI cuts the 3’ cloning site bluntly, 
where XhoI leaves a sticky end when cutting the 5’ cloning site, open for binding of the designed oligos to 
complement the restriction ends. B) Exert of Pll3.7 plasmid sequence where we can see the cut sequenc-
ing recognized by restricted enzymes. Figures created with SnapGene ® Viewer 3.3.3 program. 
 
3.4. gRNA and shRNA design 
3.4.1. gRNAs  
Individual gRNA expression vectors were previously designed by Pina’s group 















tables 1 and 2) were reconstituted with DEPC-Treated Water to the stock concentration 
of 100µM. gRNA were design to fit and attach in the linearized pKLV2 vector. So that, 
Forward oligos should start with CACCG from 5’ to 3’. On the other side, the Reverse 
oligos should start at AAAC from 5’ to 3’. This way, the ds-oligos would attach to the 
pKLV2 plasmid, as we can observe in Figure 1 (pKLV2 plasmid when cut with BbsI). 
 
Table 4 - Sequences (5’-3’) of forward (Fw) and reverse (Rv) guides for human MAT2A gene. 
Human Guides  Sequences (5’-3’) 
gMAT2A - 1 Fw CACCGAGTCACCAGATATTGCTCA 
Rv AAACTGAGCAATATCTGGTGACTC 
gMAT2A - 2 Fw CACCGCACAAGCTAAATGCCAAAC 
Rv AAACGTTTGGCATTTAGCTTGTGC 
gMAT2A - 3 Fw CACCGTTACTTGAGTTTTAGAATC 
Rv AAACGATTCTAAAACTCAAGTAAC 
gMAT2A - 4 Fw CACCGTGCAGTATATGCAGGATCG 
Rv AAACCGATCCTGCATATACTGCAC 




Table 5 - Sequences (5’-3’) of forward (Fw) and reverse (Rv) guides for human MAT2A gene. 
Mouse Guides  Sequences (5’-3’) 
gMat2a - 1 Fw CACCGAGAATCTGGGCGTAACCA 
Rv AAACTGGTTACGCCCAGATTCTC 
gMat2a - 2 Fw CACCGACAAGCTAAATGCCAAAT 
Rv AAACATTTGGCATTTAGCTTGTC 
gMat2a - 3 Fw CACCGCGGTCAAGATGAACACCT 
Rv AAACAGGTGTTCATCTTGACCGC 
gMat2a - 4 Fw CACCGGTCACCAGATATTGCCCA 
Rv AAACTGGGCAATATCTGGTGACC 




Short hairpin RNAs were constructed to fit in our lentiviral backbone for later 
transduction of Oci-AML3, MOLM13. shRNAs had to be read by a polymerase III 
promotor. Two short hairpin RNAs were designed for MAT2A gene, to increase the 
probability of knockdown. Oligo’s were synthesized (Sigma-Aldrich) with the follow-
ing sequence:  
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MAT2A sh1: 5’- 
TAGCAGTTGTGCCTGCGAAATAGGGATCCTATTTCG-
CAGGCACAACTGCTTTTTTTC-3’ 
MAT2A sh2: 5’- 
TGTTCAGGTCTCTTATGCTATTGGGATCCAATAGCATAAGAGAC-
CTGAACTTTTTTC-3’ 
In order to fit the lab’s shRNA library, few variations were made in the hairpins 
from Sigma-Aldrich library: The start base was adjusted from CCGG to T; the loop se-
quence was adjusted from CTCGAG to GGGATCC (recognized by BamHI restriction 
enzyme) and one T-base was added to the poly T-tail. 
Both forward and reverse oligos were reconstituted with DEPC-Treated Water, 
to the stock concentration of 100µM. 
 
3.5. Cloning gRNA and shRNAs: annealing, ligation and 
transformation 
The following protocol was individually used for both gRNAs or shRNA. 
1.2 µL of each sense and antisense oligonucleotides were annealed with 1µL of 
EcoRI buffer (NEB) and DEPC-treated water to perform a 10 µL reaction. The reac-
tions were placed in a PCR (Polymerase Chain Reaction) machine, thermal cycler (G-
Storm GS0004M). The program was set to start at 95 °C for 4 min, followed by 70°C 
for 10 min and then ramped down to 20 °C at 0.1 °C/sec, ending at 4 °C for 10 min.  
The annealed ds-oligos, gRNAs and shRNAs, were then ligated into the BbsI 
site of an already linearized pKLV2-U6gRNA(BbsI)-PGKpuro2ABFP (previously di-
gested with BbsI) and into the digested (with XhoI and HpaI) vector pLL3.7, respective-
ly. The ligation reaction was established using 1µL of enzyme T4 Ligase (BioLabs), 
1µL of 10X buffer for T4 ligase (BioLabs), 1 µL of linearized backbone in the case of 
pKLV2 and 2 µL of linearized backbone in the case of pLL3.7, 5µL of the annealed 
oligos and DEPC-water to make up a 10µL reaction. Two controls were made, one by 
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adding H2O instead of ds-oligos, which quantifies incompletely digested and re-ligate 
vectors. In the other control, H2O was used to replace the T4 ligase, which can cross out 
the undigested vectors. The reactions were left incubating overnight at room tempera-
ture. 
Afterward, 2µL of ligation products were transformed individually into 15µL al-
iquot of competent Cells (NEB® Stable Competent E. coli (BioLabs) for pKLV2 plas-
mid and Stellar Chemically Competent Cells (Clontech) for pLL3.7 plasmid). The com-
petent cells were incubated on ice for 30 minutes, followed by a heat shock at 42 °C for 
30 seconds and returned on ice for 2 minutes. To those cells were added 200 µl of Lys-
ogeny broth (LB) broth media, where they were left incubating for 1 hour at 30-37°C 
and 250 rpm in a Thermo-Shaker (Grant-bio, PCMT), which allowed the cells to recov-
er. 
200 µL of transformed bacteria with pKLV2 plasmid and 80 µl of culture with 
pLL3.7 plasmid were then plated on LB-agar plates containing 100 μg/mL ampicillin 
and they were incubated overnight at 37ºC. If transformation was successful, meaning 
there were few bacterial colonies in the controls compared with the sample colonies, 3-8 
bacterial colonies were inoculated into 5 mL LB with 5 µL ampicillin, using inoculation 
loops (Nunc™) and were incubated overnight at 37°C, 225 rpm, which allowed the cells 
to recover. 
Bacterial colonies were then miniprepped to isolate plasmid DNA using QI-
Aprep® Spin Miniprep Kit 50 (QIAGEN), (see Annexes, 7.1.). Ultimately, DNA con-
centration was measured by NanoDrop Lite Spectrophotometer (Thermoscientific). 
 
3.5.1. Glycerol stocks 
In Eppendorf® Safe-Lock microcentrifuge tubes of 2 mL with 150 µL of glyc-
erol 99%, was added 850 µL of bacterial culture. The mixture was vortexed a few sec-




3.6. Screen for positive clones 
3.6.1. gRNA clones – BbsI digestion 
A first screen was performed prior to sequencing: digestion reactions with BbsI 
were established to each gRNA sample in order to exclude the non-digested samples, as 
those ones would not have the gRNA oligos incorporated. If the samples were positive, 
BbsI would not cut the plasmid, because once the gRNAs are incorporated, BbsI re-
striction site is no longer present. In figure 13 in results we can see all the samples are 
positive, as BbsI enzyme could not cut the plasmid, as it did with positive control. 
Digestion reactions were set up using a MasterMix (MM) containing (per reac-
tion): 0.5µL of BbsI enzyme (Thermo Scientific), 2 µL of G buffer (10x buffer Thermo 
Scientific) and 7.5 µL of water/per reaction. The MM was then combined with 10 µL of 
each DNA sample in a concentration of approximately 150 ng/µL. Two controls were 
made: a negative control with a DNA sample without the sequence recognized by the 
BbsI enzyme (5’ GAAGAC 3’, 3’ CTTCTG 5’) and a positive control. The samples 
were incubated at 37 °C and after one hour, the temperature increased up to 65°C for 20 
min to inactivate the BbsI enzyme. Afterwards, the samples were run on a 0,8% agarose 
gel in 1x TAE (Tris-acetate-EDTA, CIMR) with a DNA ladder as reference (BioLabs) 
(see Figure 13 in results). SYBR Safe DNA gel stain (Invitrogen) was added to the gel 
to enable DNA visualization. Two positive clones for each gRNA were sent for se-
quencing to Source Bioscience Sequencing, using the pKLV Forward Primer with the 
sequence: CGATACAAGGCTGTTAGAG, in a concentration of 3.2 µmol/µL. 
 
3.6.2. shRNA clones – PCR screening and BamHI digestion 
The isolated bacterial plasmid DNA was screened for successfully ligated clones 
by PCR, making use of the ThermoCycler (G-Storm GS0004M). Primers were used as 
follows: Forward primer- CTGTTCTTTTTAATACTAGC, and Reverse primer: 
TATTAGGTCCCTCGACCTGCTGG, represented as Primer 1 and 2 respectively in 
Figure 2. 
PCR reactions were set up by making a MM containing (per reaction): 10 µL 
Taq MasterMix (QIAGEN), 1 µL of each primer (fw and rv, 100 μM stocks) and 7.5 µL 
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RNAse free water. 19.5 µL of the MM was added to the PCR tubes and 0.5 µL of the 
miniprepped DNA for each different clone was added. Per PCR three controls were re-
quired: a blank control using RNAse free water instead of plasmid DNA to check for 
contamination; a positive control using 0.5 µL of the LLX-vector containing a shRNA 
to recognize positive clones and a negative control using 0.5 µL of the original vector to 
distinguish negative clones. Thermocycler settings used were as follows: 94°C for 3 
min, 40x [94°C for 30 s, 57°C for 30 s, 72°C for 1 min] and lastly 72°C for 10 min. 
Thereupon, multiplied DNA was run on a 2% agarose gel at 50 volts for visualization 
with a DNA ladder (Biolabs), and the gel results are represented in figure 21 in results.  
Also, digestion reactions were set up using a MM containing (per reaction): 
0.5µL of BamHI enzyme 20.000U/Ml (NEB – New England Biologicals), 2 µL of buff-
er 3.1 10X (NEB – New England Biologicals). DNA in a concentration between 600-
700 ng/uL and RNasefree water were added to a final volume of 20µL per reaction. 
Two controls were made: a negative control (pLLx3.7 RNA; 235.5 ng/µL): DNA sam-
ple without the loop sequence recognized by the BamHI enzyme (5’ GGGATCC 3’) 
and a positive control (LLX CTRL; 624.5 ng/µL): DNA sample with a short hairpin 
sequence recognized by BamHI enzyme. The samples were incubated 1h30min, at 37 
°C, before running on a 0,8% agarose gel with 1x TAE (Tris-acetate-EDTA, CIMR) 
with a DNA ladder (BioLabs). SYBR Safe DNA gel stain (Invitrogen) was added to the 
gel to enable DNA visualization. Resulted gel is represented in figure 22. Four positive 
clones for each shMAT2A were sent for sequencing to Source Bioscience Sequencing, 
using the Fw (CTGTTCTTTTTAATACTAGC) and Rv (TATTAGGTCCCTCGAC-
CTGCTGG )-primers in a concentration of 3.2 µmol/µL.  
 
3.7. Isolation of bacterial plasmid DNA 
3.7.1. gRNA clones  
The clones with a positive sequencing result were therefore transformed again, 
using 0.5 µL of DNA and 5 µL of NEB-Stable cells. Thenceforth following the trans-
formation protocol as described above. After the two days incubation at room tempera-
ture, a single colony was inoculated in 3 mL of LB, containing 3 µL ampicillin (final 
concentration of 100µg/mL) and incubated overnight at 37°C, 225 rpm. 3 mL of bacte-
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rial suspension was transferred to an Erlenmeyer flask with 50 mL of LB and 50 µL of 
ampicillin and was incubated again overnight at 37°C, 225 rpm. To isolate bacterial 
plasmid DNA a Midiprep (Invitrogen) was performed (see Annexes, 7.3.).   
 
3.7.2. shRNA clones 
The clones with a positive sequencing result were therefore midipreped (Invitro-
gen) (see Annexes7.3.) to isolate bacterial plasmid DNA. In shRNA experiment glycer-
ol stocks mentioned above were used.  
 
3.7.3. DNA quantification 
DNA concentration was measured by NanoDrop Lite Spectrophotometer 
(Thermoscientific). Once isolated, DNA should be assessed for both concentration and 
integrity/quality. DNA concentration (in ng/μL) should be determined by 260 nm ab-
sorbance. The purity of the RNA is determined by the 260 nm (A260) and 280 nm 
(A280) ratio (A260/A280). The DNA purity should preferably be between ratios of 1.8 
for DNA and 2.0 for RNA. 
 
3.8. Lentivirus production and transduction 
1.28 μg of pCMV 9.81 (packaging plasmid) and 1.28 μg of pMD2G (envelop 
plasmid) (Addgene) were added to 1.92 μg of pKLV2 vector with the gRNA or shRNA 
of interest, per flask equivalent. Once the reactions were settled, with TE (Tris-EDTA) 
buffer until a 9.3 µL volume, the DNA mixes were added to the transfection agents (237 
μL Optimem and 15,8 μL transIT per flask to transfect) and were incubated for 20-30 
minutes at room temperature. After that, the solutions were separately wisely dropped 
into T75 flasks, cultured with 293T cells attached on one surface with 8 mL of DMEM 
(D10) media. After swirling the flasks, they were left incubating at 37°C and 5% CO2. 
Viral supernatant was harvested 48h and 96h after transfection, centrifuged at 400g for 
5 minutes to discard spliced cells and the remained supernatant was centrifuged again 
overnight at maximal speed (3200 rpm), 4°C, acceleration 6 and deceleration 2. The 
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medium was replaced with fresh DMEM media (8 mL) 24h after transfection. Virus 
were then re-suspended in preferably 30 µL per flask equivalent. 
 
3.8.1. Viral Transduction with guide RNAs  
Delivery of viral of gmMat2a and empty vector was achieved by Viral Trans-
duction of FLT3 MLL/AF4 Cas9 and FLT3 MLL/AF9 Cas9. Experimental set up was 
performed in 24-well plates with 3 x 105 cells/well and viral supernatant were added to 
1 mL of culture medium as follows: 1 flask equivalent of empty vector and 1/5 flask 
equivalent for mMat2a guides (a set of 5 guides). Cells were incubated for an overnight 
period at 37°C, 5% CO2. 
Delivery of viral of gMAT2A and empty vector was achieved by Viral Trans-
duction of MOLM13, Oci-AML3 and Kasumi1 cell lines.  
Related to MOLM13 and Oci-AML3, experimental set up was performed in 48-
well plates with 5 x 105 cells and viral supernatant were added to 500 µL of culture me-
dium as follow: 1 flask equivalent of empty vector and 1/3 flask equivalent for empty 
vector and MAT2A guide.  
In the transduction of Kasumi1 experimental set up was performed in 48-well 
plates with 1 x 105 cells and viral supernatant were added to 500 µL of culture medium 
as follow: 2 flasks equivalent of empty vector and 1/2 flask equivalent for each MAT2A 
guide.  
Lastly, cells were incubated for an overnight period at 37°C, 5% CO2. 
 
3.8.2. Viral transduction with short hairpin RNAs for MAT2A gene 
Delivery of viral of shMAT2A and shCTRL was achieved by Viral Transduction 
Transduction of Oci-AML3 cells. Experimental set up was performed in 24-well plates 
with 5 x 105 cells and viral supernatant were mixed in 1 mL of culture medium as fol-
lows: 1.5 flask equivalent of shCTRL, of 48h and 96h after collection, separately, and 
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1.5 flask equivalent for shMAT2A, in duplicate as well, using the 48 h and 96 h collec-
tion.  
 
Subsequently all transduced cells were incubated overnight at 37°C and after 
transduction, cells were washed 2 times with PBS (Phosphate-buffered saline buffer) 
(Sigma-Aldrich) and once with Culture media, further placed in culture as mention 
above. Cells controls were made for each cell line. The lentiviral vector that carries the 
guide also expresses BFP as a reporter, so that transduction efficiency was quantified by 
Flow cytometry analysis. 
 
3.9. FACS and FACS-sorting  
After washing, cells transduced with guideRNAs were analyzed by a fluores-
cence-activated cell sorting (FACS) for BFP expression in a flow cytometry (Gallios, 
Beckman Coulter) to evaluate the efficiency of the transduction, since the lentiviral sys-
tem uses blue fluorescent protein (BFP) as a reporter. Cells transduced with shRNA 
were analyzed for GFP expression. To analyze, 50 µL of each sample were supplement-
ed with 200uL of MOJO-buffer 1x (BioLegend). A negative control was used to set the 
gating strategy, as we can see in Figure 9. 
 
 
Figure 9 - Example of sort plots. A) Gating strategy for Gallios flow cytometry. First histogram shows a 
gate to select living cells, through forward scatter-FS and side scatter-SS. FS detects cell size and SS 
B 
A 
Live gate Singlets 
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determines the granularity and complexity of the cell. To exclude doublets, a second gate was established 
contemplating only living cells (SS Width vs. SS Area). Then, singlets were gated on BFP positivity. The 
third histogram shows the negative control, with uninfected cells, in which we based to determine the 
negative population for BFP positive. B) Example of a BFP positive population, that shows the percent-
age of transduced cells. These graphs resulted from MOLM13 cells. 
 
Upon confirmation of the presence BFP positive population, samples were sort-
ed in order to obtain the BFP+ cell population. Again, in case of shRNAs, the cells were 
sorted for GFP expression, instead of BFP. 
Cell suspension were span down at 2000 rpm for 5 min and the supernatant was 
discarded. Cell pellets were resuspended in MOJO buffer 1x (BioLegend) and trans-
ferred into sort tubes. Oci-AML3, MOLM13 and Kasumi1 cell lines were filtrated be-
fore sorting. The cells were sorted using BD INFLUX sorter. BFP and GFP positive 
cells were sorted into R20 media. All FACS analyses were performed on Kaluza Analy-




Figure 10 - Example of FACS analysis and sort of living cells transduced with BFP. A) Gating selection 
using a negative control unstained. i. shows the gate for live cells (SSC-A vs. FSC-A). ii. From these a 
second gate was drawn to separate singlets from doublets (FSC-W vs. FSC-A). iii. Singlets were gated for 




i ii iii 
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in the culture. All histograms correspond to MOLM13 cells; A- MOLM13 CTRL, B- MOLM13 transduced 
with gMAT2A. 
 
3.10. Analysis of viability and cell growth 
Viable cells were determined by trypan blue (TB) (Sigma Aldrich) exclusion. It 
was based on the principle that live cells possess intact cell membranes, whereas dead 
cells do not. Cell suspensions were mixed with TB dye and examined in an optical mi-
croscope to determine whether cells take up or exclude dye. The viable cells had a clear 
cytoplasm whereas the nonviable cells had a blue cytoplasm. Both live and dead cells 
were counted. From the number of live cells and the respective concentration in culture 
(live cells/mL) for each day, graphs with culture expansion were drawn taking into ac-
count all dilutions made during the follow up. Also, a graph showing the percentage of 
dead cells in culture per day was designed, through dead cells counting. These graphs 
were made for each cell line and for each experiment, as seen in Results section. 
 
 
3.11. RNA isolation, primer design and RT-qPCR 
After placing in culture BFP positive progenitors collected with FACS sort (Oci-
AML3, MOLM13), RNA was extracted from the samples, using TRIzol reagent (Ther-
moFisher). 200 μL chloroform were used to separate the organic and aqueous phase, by 
denaturing protein and settling it to the bottom. After collecting of the aqueous phase, 
5/6 of this volume of isopropanol (IPA, Honeywell) and 2 μL GenElute TM-LPA (Sig-
ma-Aldrich) were added, respectively to aggregate the RNA to form a pellet and to aid 
recovery of the RNA during ethanol precipitation with 800 uL EtOH-80%. The extract-
ed RNA was preserved in 20 uL RNasefree Water. 
After, it was used to generate first-stand cDNA during reverse transcription. For 
a single reaction 4 μL 5x VILOTM Reaction Mix and 2 μl 10x SuperScriptTM Enzyme 
Mix (both Invitrogen) were needed, together with a certain amount of RNA (dependent 
on qPCR reaction) and DEPC-treated water to get a total volume of 20 μl per reaction. 
Primers and probes were used to perform the RT-qPCR (Quantitative reverse transcrip-
tion polymerase chain reaction).  
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DNA generated by RT-qPCR was amplified with primers for the different 
gRNA constructs, which were designed (https://www.ncbi.nlm.nih.gov/tools/primer-
blast) to span an exon-exon junction, ideally have a length between 18-22 base pairs and 
a melting temperature (Tm) of 60°C, and have a PCR product size between 70-150 base 




Human MAT2A Forward TGTGCCTGCGAAATACCTTGA 
Reverse CCCCAACCGCCATAAGTGTC 




Reverse Transcription-qPCR reactions were performed using Brilliant II SYBR 
Green qPCR Master Mix (Agilent Technologies) in a CFX96 RealTime System (Bio-
Rad). Reactions were set up by making a master mix containing (per reaction): 12.5 uL 
SYBR Green, 0.125 uL of each Fw and Rv primer and 7.8 uL RNasefree water. To 
these reactions, 2 uL of DNA template was added. NTC controls without the DNA tem-
plate were also made. qPCR program settings used were as follows: 50°C for 30 min, 
95°C for 10 min, 39× [95°C for 30 s, 60°C for 1 min], 65°C for 30 s and lastly a melting 







4.1. MAT2A knockout abrogates proliferation of human AML 
cell lines 
 
I sought to validate the results of the Tzelepis screen through delivery of 5 guide 
RNAs targeting the MAT2A gene to human AML cell lines with constitutive expression 
of Cas9. These included the OCI-AML3 and MOLM13 lines in the original screen, as 
well as Kasumi-1 cells, which had not been previously tested. 
In all experiments, triplicate wells were set and infected independently with the go 
to analyse each of the cell lines in triplicate. However, due to low efficiency of trans-
duction, in most cases sorted cells were pooled and analysed in a single representative 
experiment, which is reported.  
Results present how human AML cell lines, such as Oci-AML3, MOLM13 and 
Kasumi-1 react to MAT2A knockout (KO). It will validate screen results and under-
stand the mechanism underlying the dependency of MAT2A in AML cell lines. 
For this, 5 individual guideRNAs for human gMAT2A were cloned into the len-
tiviral backbone pKLV2 seen in Figure 11 (see sequences in Materials and Methods). 
 
 
Figure 11 – Excerpt of pKLV2 plasmid sequence showing BbsI cloning sites either side of the guide RNA 
scaffold. BbsI digestion generates 2 unique cohesive ends used for insertion of individual gRNAs. 
 
After the ligation between pKLV2 lentiviral vector and an annealed guide, the 
sequence that would result is as follows: 
  
Figure 12 – Excerpt of pKLV2 plasmid sequence with the 2th guide designed for human MAT2A gene (see 
sequence in Materials and Methods) incorporated. Guide RNAs are designed as two complementary 







oligonucleotides with unique ends that complement the unique cohesive ends generated through BbsI 
digestion of pKLV2. 
 
Guide RNA annealing was verified by digestion of recombinant pKLV2 plasmid 
DNA with BbsI. Unlike non-recombinant pKLV2, gRNA incorporation destroys the 
BbsI restriction sites, and no plasmid linearization is produced upon digestion (Figure 
13). Candidate recombinant clones were then confirmed by Sanger sequencing. The 
agarose gel showing the results is underneath: 
 
Figure 13 – Example of a BbsI digestion gel. This gel shows digestion bands of samples with gRNA DNA 
(non-digested, 1-5 and digested, 1’-5’) and the positive and negative controls, represented as non-
digested (ND) and digested (D). 
 
The clones most likely to be recombinant, were sent to sequencing (see one 
matching sequencing example further ahead in mouse cell lines results) and after con-
firming the positive ones, I selected one verified clone for each guide and prepared len-
tiviral particles for guide delivery into human AML cell lines. Cells were transduced 
with empty (non-recombinant) pKLV2 lentiviral particles, as control. After transduc-
tion, cells were sorted on the basis of expression of the Blue Fluorescent Protein (BFP) 
reporter and their respective cultures monitored for expansion and cell death.  
 
For Oci-AML3 cell line, culture expansion and % of cell death graphs (Figure 
14) are shown underneath. We can see that until day 4, Oci-AML3 cells with EV prolif-
erate in a stagnant way. After day 4, EV culture is vividly marked by a growth curve, in 
which the % of cell death is minimal, reaching only 2,5%. On the other hand, cells 
transduced with MAT2A guides remain in an almost constant cellular concentration 





















































tive cells, we see that MAT2A guide cells had a lower survival rate (75-80%) compar-
ing with EV cells (94-100%). 
 
Figure 14 - A) Live cells /mL and B) % of Cell Death of one performed experiment (n=1). In a general 
way, Oci-AML3-EV sample proliferates and increases the cell culture. On the other side, MAT2A sample 
is marked by cell death, with no room to increase cell culture, so that it does not expand like EV sample 
does. 
For MOLM13 cell line, culture expansion and % of cell death graphs (Figure 15) 
show that there is a clear difference between expansion of both variants. While EV 
sample is marked by a three-growing phase proliferation (until day 3 with a lethargic 
growth, from day 3 until day 5 with a moderately growth and since day 5 with a huge 
proliferation), cells transduced with MAT2A have half of the cells dying until the last 2 
days of the follow-up, decreasing then until a % of death around 25%, once the culture 
decreases the concentration day by day. 
  
Figure 15 - A) Live cells /mL and B) % of Cell Death of one performed experiment (n=1). Here, there is 
no expansion in cell culture of MAT2A sample once the culture growth does not increase and % of cell 
death is decreasing with the concentration decrement. The opposite is verified in EV sample, inasmuch 





































































































For Kasumi1 cell line, culture expansion and % of cell death graphs (Figure 16) 
show that Kasumi1 cells with EV guide have a non-homogenic path, though leaving out 
the day-4 count, once it can be a counting error, cells evidence a good proliferation rate 
without much percentage of cell death until the last day, marked by a decrease in prolif-
eration, which may be due to the increment of cell death. Meanwhile, cells transduced 
with MAT2A guides survived well until day-4 even having a constant cell growth line. 
After that day, proliferation decreased, as well as the survival rate, reaching levels of 
cell death around 60%. 
  
Figure 16 - A) Live cells /mL and B) % of Cell Death of one performed experiment (n=1). EV sample has 
a higher culture expansion comparing with MAT2A sample, which is marked by a 50% of cell death in 
the last days of the followed experiment. 
 
 In general, these graphs show AML cell lines proliferating and growing when 
they are transduced with empty vectors. By changing transduction to vectors for 
MAT2A guides, the three different cell lines experience a decrease in proliferation, hav-
ing constant cell growth paths and a big percentage of death cells, not showing an in-
crement of cell numbers. 
I have thus independently confirmed human AML cell line dependency on 
MAT2A for survival, and extended the results of the Tzelepis screen to Kasumi-1 cells, 
which represent a distinct common subtype of AML. 
I did not initially include the candidate non-responsive MV4.11 cell line (see 
Figure 6), which would have been important to exclude global toxicity. However, I have 
investigated mouse primary cell lines carrying corresponding MLL-AF4 and FLT3-ITD 

















































MOLM13) to the same end. Nonetheless, meanwhile in the lab, MV4.11 cell line has 
been studied independently using specific inhibitors. 
 
4.2. Mat2a knockout abrogates proliferation of transformed 
primary mouse bone marrow cell lines 
 
The same procedures of human AML cell lines were done for primary mouse 
BM cell lines, MLL-AF4 FLT3ITD and MLL-AF9 FLT3ITD. In this case, 5 individual 
guideRNAs for mouse gMat2a were cloned into the lentiviral backbone pKLV2, ho-
mologously to Figure 11 (see sequences in Materials and Methods). 
After the ligation between pKLV2 lentiviral vector and the annealed guides as 
well as the first verification of recombinant pKLV2 plasmid DNA through digestion 
with BbsI and the second verification by sending to sequencing the clones most likely to 
be recombinant, the data was received and Figure 17 is an example of a matching se-
quence. In this case it matches with mouse gMat2a-5-Fw (see sequences in Materials 
and Methods). Of note, it would only need one wrong base to be a non-recombinant 
sequence. 
 
Figure 17 - Example of a matching sequence of a positive clone with a mouse forward guide (Fw: CAC-
CGAGAAACTGTTGCTAAAAC), done by Source BioScience UK Limited.  
 
Then, the recombinant clones verified by sequencing results were individually 
selected to produce lentiviral particles, for later transduction of transformed AML 
mouse BM cells. 
Primary mouse BM cells were transduced as well with empty (non-recombinant) 
pKLV2 lentiviral particles, as control and after transduction, cells were sorted on the 
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basis of expression of the Blue Fluorescent Protein (BFP) reporter and their respective 
cultures monitored for expansion and cell death, like it was done for human cell lines. 
For transformed MLL-AF4 FLT3ITD primary mouse BM cells, culture expansion 
and % of cell death graphs are presented below (Figure 18). MLL-AF4 cells proliferate 
less comparing with human AML cell lines and after being sorted, EV transduced cells 
started with a lower number of BFP+ cells than Mat2a ones. During the follow-up, EV 
sample proliferate, having the biggest rate from day 4 to 6. mMat2a sample decreased 
cellular concentration in the first 3 days, where since then remained with an approxi-
mate similar cellular concentration, once the cells star to die, reaching a cell death per-
centage of 93%. * Not done. 
 
Figure 18 – A) Live cells /mL and B) % of Cell Death of one performed experiment (n=1). While EV 
sample recovers and we see a huge proliferation, the same does not happen with the Mat2a sample, in 
which the % of cell death surpassed the proliferation and so Mat2a sample ends up dying. 
 
For transformed MLL-AF9 FLT3ITD primary mouse BM cells, proliferation and 
% of cell death graphs MLL-AF9 show that cells proliferate less comparing with human 
AML cell lines. Technical replicates which are repeated measurements of the same 
sample were made three times. The results graph displays the average values and stand-
ard deviation (SD) of the mean, which is represented by the error bars. During the fol-
low-up, both samples multiply, having the EV cells the biggest proliferation. As seen in 
the SD error bars, in the last day of experiment, there is an enormous range of possible 
results, not allowing a clear analyse. So that, it is difficult to take reliable conclusion. 






















































die more comparing with cells with EV. mMat2a sample shows a % of cell death in-
creasing between 37 and 49%, while EV sample increase between 19 and 39%. 
 
Figure 19 - A) Live cells /mL and B) % of Cell Death of a performed triplicate experiment (n=3).  
 
In previous reports, it is known that MLL-AF9 FLT3ITD cells are equivalent to 
MOLM13 cells in what concerns gene expression profiling (62). Analogously, MLL-
AF4 FLT3ITD cells are equivalent to the AML cell line MV4-11 (63), which one was 
studied in CRISPR screen with results of a non-dependency of MAT2A to survive (22).  
Somewhat surprisingly, I observed a dependency of MLL-AF4/FLT3ITD-
transformed primary BM cells on Mat2a, while MLL-AF9 FLT3ITD cells were unre-
sponsive to Mat2a depletion. This may reflect differences between mouse and human, 
and warrant further investigation in additional transformed primary mouse BM clones. 
Also, it is possible that additional mutations present in the complex karyotype displayed 
by both MV4.11 and MOLM13 cell lines significantly modify the response to MAT2A 
loss, in a way that is not captured by the primary mouse lines. Notwithstanding the dif-
ferences between mouse and human models, the results obtained in mouse confirm cell 
type-specificity in Mat2a dependency, which is important when considering its thera-
peutic potential. Once again technical issues prevented replication of the MLL AF4 
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4.3. Functional Validation of CRISPR screen 
In order to validate dependency of AML cells lines on MAT2A expression by an 
independent means, I designed multiple shRNAs (See Materials and Methods) targeting 
the MAT2A coding sequence in order to achieve MAT2A knockdown by RNA interfer-
ence. Those were cloned into the lentiviral vector pLL3.7 and to fulfil the cloning pro-
cedure, pLL3.7 was digested with XhoI and HpaI restrict enzymes and the linearized 
DNA vector was cut out from the gel and further purified (QIAquick Gel Extraction Kit, 
QUIAGEN) as follows: 
 
Figure 20 - Digestion gels. A) showing the negative control non-digested and both wells with digested 
product. B) showing the cut out of plasmid DNA to former use gel extraction kit. 
 
After cloning procedure (see Materials and Methods) was the sequence valida-
tion step, to make sure we had the shMAT2A incorporated inside pLL3.7. A PCR 
screening and a BamHI digestion were performed to select the most likely positive 
clones and then send them for sequencing. The results are as follows: 
 
Figure 21 – A) 1 Kb Plus DNA ladder for a 2% agarose gel with quantity of base pairs per bar repre-
sented. B) Gel of DNA multiplied by PCR screen, run on a 2% agarose gel. First loading well contained 






















controls to be able to detect positive clones, and a blanc control to check for contamination. Positive 
samples, which are the ones with the shRNA inserted, are represented in the same line of the positive 
control, a little higher than the negative samples. These last ones, as we can see clearly in the samples 6 
and 8, do not have the shRNA inserted, since the used primers cannot amplify the inserted shRNA region. 
Red arrows indicate positive clones, which were sent for sequencing. This gel shows bands of 
shMAT2A_1 (1-8) and shMAT2A_2 (9-12) DNA. 
 
 
Figure 22 - BamHI digestion for screen for positive clones, run on a 0.8% agarose gel. First loading 
well, in both gels, contained the 1 Kb plus DNA ladder, followed by the samples, in which the numbers 
(1) represent undigested plasmid and the numbers followed by the sign ‘ (1’), represent the digested vec-
tor. Positive and negative controls run in the gel 2, in the last 4 wells. Positive clones had the same ap-
pearance as the positive control. When digested, the positive clones appear as linearized plasmid, while 
the non-digested appears as a circular plasmid. Red arrows indicate positive clones, which were sent for 
sequencing. This gel shows the difference of digested (1-12) and non-digested (1’-12’) samples of 
shMAT2A_2. 
 
Then, the most possible positive clones were sent for sequencing and the follow-
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Figure 23 - Example of matching sequences of a positive clone with shMAT2A, Fw and Rv (shMAT2A-2 
Fw:TGTTCAGGTCTCTTATGCTATTGGGATCCAATAGCATAAGAGACCTGAACTTTTTTC), done by 
Source BioScience UK Limited.  
 
Being sure about the positive clone, lentiviral particles were produced to infect 
Oci-AML3 cell line. Right after, the transduced cells were sorted for GFP+ positive 
cells and cultured for testing of MAT2A knockdown and evaluation of the effects of 
MAT2A reduction on growth and death of transduced OCI-AML3 cells. 
 
4.3.1.Validation of Knockdown 
To validate the knockdown (KD) of MAT2A, another RT-qPCR were performed 
by Pina’s lab group with Oci-AML3. Like previously, ACTB and GAPDH were both 
used as controls. Besides, two technical replicates were made, so that a standard devia-







Figure 24 - MAT2A expression relative to ACTB and GAPDH controls, individually. Relative to both 
controls, the expression level of MAT2A gene dropped to 27 and 25%, respectively. Standard Deviation 
error bars indicate that KD relative to ACTB has an error of 2% and relative to GAPDH the error can go 
up until 7%.   
 
The graph shows a marked decrease in the expression of MAT2A gene, repre-
sented by the orange bars, for both controls, with a level of knockdown of just under 
75%. Thus, with this functional validation of knockdown we confirm the true depend-
ency of MAT2A for cells development. 
Similar to my observations in the MAT2A-directed CRISPR experiments, I ob-
served decreased growth and enhanced cell death in the knockdown cultures. Specifical-
ly, growth curves and cell death were followed-up for 6 days after GFP+ sort collection 
and two technical replicates were made. Also, cells were counted with Trypan Blue 
method, described in Materials and Methods. Cell profile graphs are underneath (Figure 
25). From day 1 to day 3, live cells path seems similar inside each variant individually: 
LLX CTRL samples increase proliferation while in shMAT2A samples, we do not ob-
serve cell expansion. Until day 6 LLX CTRL cells start to proliferate in a more ad-
vanced rate, comparing with shMAT2A condition in which one sample (shMAT2A-1) 
remains in almost constant cellular concentration and the other sample (shMAT2A-2) 
end up dying. In cell death graph, achieved through the % of trypan blue positive cells, 
we see that after the first day, all cells recover, decreasing the % of cell death. By day 6, 
LLX CTRL-1 decrease to 80% cell survival and LLX CTRL-2 recover, presenting 
100% of survival, while shMAT2A-2, as described before, ends up dying and 
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Figure 25 – A) Live cells /mL and B) % of Cell Death of a performed duplicate experiment (n=2). In 
general, LLX CTRL samples increase proliferation, reducing cell death. Meanwhile, in shMAT2A cells, 
we do not observe cell culture expansion, and cell death path is not regular, decreasing day-by-day in 
one sample (shMAT2A-1) and decreasing first until day 3 but ending up dying in the last day in the other 
sample (shMAT2A-2), with a 100% of cell death. 
 
Looking over the graphs, we see that cells transduced with shCTRL have a 
higher expansion during the 6 days, especially after day-3, comparing with cells with 
shMAT2A. At the same time, % of dead cells shows a considerable death rate in the 
first day, with an average of 43% for shMAT2A and 41% for LLX CTRL. From the 
first day seems like the cells recovered until day 3, in the sense of dying less or prolifer-
ating more.  
Linking both graphs, it is correct to affirm that shMAT2A cells did not prolifer-
ate as the CTRLs (Figure 25 – Culture expansion) because they were dying more (Fig-
ure 25 – Cell death). Accordingly, and once again, we show that MAT2A gene can be 
related with the survival and proliferation of Leukemic cells, once we demonstrated a 
KD on MAT2A gene and a decreasing in proliferation rate (or cellular survival) in Oci-
AML3 shMAT2A samples. This achievement can come up with a new way of treatment 
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4.4. Confirming direct validation of CRISPR screen 
 
I attempted to confirm gene expression knockout of MAT2A by quantitative RT-
PCR analysis of Cas9-expressing OCI-AML3 and MOLM13 cell lines transduced with 
a pool of MAT2A-directed guide RNAs. I extracted RNA and synthesised cDNA from 
transduced cells cultured for 7 days in the presence of the guides. I used 2 pairs of pri-
mers directed to MAT2A coding sequence located upstream and downstream of the 
region targeted by the guide RNAs. Figure 26 shows the coding sequence (CDS) of 
MAT2A mRNA, highlighting the primers, the 5 guides for human MAT2A gene and 









Figure 26 – CDS sequence of MAT2A gene. Guides location are represented in orange rectangles. 
Primer sets are highlighted with a purple arrow and the tip and toes of the exons are also represented 
with different colour arrows for each exon. Figure was designed with SnapGene Viewer 3.3.3. Gene 
mRNA sequence was taken out from (64) 
 
Both pairs of primers were designed across exon boundaries, and generated a 
single amplicon in control and targeted samples, compatible with amplification of 
cDNA, but not genomic DNA. Figures 27 shows the dissociation curve of the primer set 





Figure 27 – A) Dissociation curve of the qPCR test with annealing temperature set at 65,25 °C showing 
high peak at ± 84,5 ºC of four populations in a n=3 experiment: MOLM13-EV, MOLM13-MAT2A, Oci-
AML3-EV and Oci-AML3-MAT2A, which correspond to MAT2A primer set that span the exons 1 and 2. 
 
I did not observe reduction or loss of MAT2A transcript in none of cell lines us-
ing both primer sets (Figures 28A and 28B), which is surprising for the downstream 
one, as at least a proportion of the NHEJ events subsequent to Cas9-mediated endonu-
clease activity were likely to have introduced premature stop codons and reduced sub-
sequent downstream transcription. Alternatively, the generation of a proportion of 
frameshift mutations would have resulted in targeting of RNA to non-sense RNA decay 
mechanisms, also leading to reduction in transcript levels. I did not have enough materi-
al to verify the levels of knockout at the level of protein production by Western blot, 
which would be the next logical experiment. 
   
Figure 28 – MAT2A expression relative to ACTB and GAPDH controls, individually, regarding both 
MAT2A primer sets. Red columns correspond to RT-qPCR using MAT2A primers spanning exons 1 and 2 
of gMAT2A samples, while green columns are related with MAT2A primers that span exons 6 and 7.  
Considering all conditions, no considerable loss of MAT2A gene expression is observed. A) Related with 
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Assuming absence of detectable knockout in cultured cells expressing the BFP+ 
guide RNA construct, one possible explanation is that the surviving cells in the culture 
failed to express the guide RNA, which is transcribed from a RNA Pol U6 promoter 
distinct from the RNA PGK promoter driving expression or BFP. More likely, the sur-
viving cells may not exhibit Cas9 activity, despite expression of the construct in the 
culture, as these were not clonally-derived. Tzelepis et al. effectively showed that 50% 
of clones did not show Cas9 activity. Another hypothesis is that these clones have taken 
over the culture upon death of the MAT2A knockout cells (22). Although this is an in-
teresting point to clarify in future experiments, the validation of the CRISPR/Cas9 re-
sults by shRNA-mediated knockdown of MAT2A expression, and more recently, by 
MAT2A chemical inhibition (performed independently from this work in the PINA lab), 





 Conclusions and Future Perspectives 
 
According to a CRISPR Dropout Screen (22) developed in order to understand 
the genetic vulnerabilities of cancer cells, 492 genes were found as AML-specific cell-
essential genes, which can be perceived as new targets for therapeutic strategies. From 
that research, the study of molecular mechanisms underlying tumorigenesis were 
thought-about as well. Among those genes, MAT2A was found to be essential for AML 
cell lines survival. The work presented in this thesis led to an initial validation of that 
CRISPR screen by independent gRNA cloning and testing in Cas9 expressing cells and 
broaden it into an additional cell line, of those ones cover in the paper. To clarify, 
MOLM13 and Oci-AML3 cell lines were shown to depend on MAT2A, according to 
the conclusions of CRISPR screen and Kasumi1 cell line allowed the extension of 
CRISPR results. In the three cell lines we validate the dependency of MAT2A once, by 
comparing with the empty vector control, cells transduced with guides for MAT2A 
decreased their proliferation and their survival rate.  
Furthermore, this work also allowed the development of tools for investigation 
of CRISPR-mediated knockout of Mat2a in mouse cells. Two different mouse model 
cell lines were searched as well, contributing to the enlargement of CRISPR results. 
Transformed MLL-AF4 FLT3ITD and MLL-AF9 FLT3ITD primary mouse bone marrow 
cells were tested for the dependency of Mat2a gene.  
Moreover, design, cloning and validation of MAT2AshRNA constructs for gene 
expression knockdown in human cells were tested and it made possible the creation of 
important tools, once shRNA knockdown is currently more easily amenable to use in 
primary patient AML cells.  
During the development of the following thesis, general caveats of data should 
have been taken into consideration and this awareness can be useful in future 
experiments. 
As explained in the result section, technical difficulties throughout replication of 
the number of the experiments was confronted so that the designed experiments were 
not possible to perform and a fool validation of the results require it to make every 
result more reliable and to take more consistent conclusions.  
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Also, experimental setbacks left us with no live cells remaining of Kasumi1, 
MLL-AF4 and MLL-AF9, so that they were not submitted to the RT-QPCR.  
Our gene of interest, MAT2A, encodes a specific isoform of MAT gene, which 
is a key enzyme in metabolism, because it catalyses the synthesis of S-
adenosylmethionine (SAM), the major methyl group donor. The process in which SAM 
is originated needs methionine and it is thought that cancer cells can be methionine 
dependent in what concerning the lack of SAM. The reason cancer cells depend on high 
levels of SAM remains to be discover. Further experiments related with the 
measurement of SAM levels produced in cells would be interesting. The relation 
between inhibition of MAT2A and the remaining capacity of cells to produce SAM can 
be a grant to study the capacity of cells to proliferate in a non-regular way. Relating this 
discovers with published data, it is demonstrated that only cancer cells are affected by 
methionine deficiency (45), which can make us consider about the therapeutic effects of 
MAT2A loss in AML cells. But it leads us to another research that must be made before 
taking any conclusions about the transversely of solid cancer cells and blood leukemic 
cells. Nevertheless, the results described here need to be tested once again in normal 
cells, i.e results must be evaluated as a function of the dependence of MAT2A on 
normal cells, in order to be a valid therapeutic which affects only AML cells. 
In this thesis we inhibited our gene of interest and we relied in the absence of the 
gene in the results. However, there are two products that can be altered when there is a 
gene inhibition: DNA and proteins. Here we only examined DNA expression, without 
checking at the protein level. The option of having expression of cDNA but no proteins 
can happen. As said before, it remains possible to have an in-frame repair with the 
production of a transcribed mRNA molecule or it could have a dissociation in gRNA 
and BFP expression which have might led to only BFP selection leaving aside MAT2A 
guides. In a future experiment, a validation of gene expression loss at the protein level 
by western-blot can be performed to detect specific MAT2A proteins using antibodies, 
instead of searching for cDNA expression.  
Nowadays despite traditional treatments for Acute Myeloid Leukemia, 10,590 
people are expected to die from this malignancy in 2017 and an estimated 21,380 new 
cases are expected in the current year (65). Research and discover new treatments are 
urgent. Besides, understanding the pathogenesis at a genomic and molecular level has 
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often come to light in different researches (66). New treatments can be developed by 
identifying cancerous cells vulnerabilities. The overall purpose of this thesis was to 
describe the study of one possible novel treatment, related with gene editing, lightening 
away the traditional options to overcome leukemias. 
Another huge contribution to the study of different and new options to cure 
leukemia is to delineate experiments to measure the metabolic and transcriptional 
consequences of depleting MAT2A.  
Moreover, one interesting approach related with pharmaceutical industry is 
related with SAM inhibitors. It was discovered some years ago a molecule that is cable 
of inhibiting MAT2A gene in primary cells. The cell-permeable fluorinated N,N-
dialkylaminostilbene (FIDAS) inhibits MAT2A-catalyzed SAM (S-
adenosylmethionine) synthesis by targeting SAM-binding pocket at the MAT2A dimer 
interface. There are two different classes of FIDAS: -3 and -5, which the last one is 
more than 2 times more potent than FIDAS-3 in inhibiting MAT2A-catalyzed SAM 
synthesis. They were shown to downregulate intracellular SAM level (by 60%; 36 h) 
with 10 µM of FIDAS-3 and 3 µM of FIDAS-5 (67). With this possibility it could be 
interesting to study the role of FIDAS in AML cell lines at the same time as a validation 
of this work inhibiting MAT2A by gene editing. Moreover, they could be used to 
support the data obtained, and to extend the investigation to patient cells in vitro and in 
vivo. 
Finally, this project led me to deeply understand the molecular basis of one 
carbon cycle and the cell machinery involved in methylation steps. It enabled the 
validation of the results concerning the loss of a vulnerable gene previously shown by 
Tzelepis et al. (22),  allowing opening the door to innovative new treatments for 
leukemia. The present work is part of a vast effort to understand the new therapeutic 
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